Translational Medicine Communications (Nov 2022)
Planning preclinical confirmatory multicenter trials to strengthen translation from basic to clinical research – a multi-stakeholder workshop report
- Natascha Ingrid Drude,
- Lorena Martinez-Gamboa,
- Meggie Danziger,
- Anja Collazo,
- Silke Kniffert,
- Janine Wiebach,
- Gustav Nilsonne,
- Frank Konietschke,
- Sophie K. Piper,
- Samuel Pawel,
- Charlotte Micheloud,
- Leonhard Held,
- Florian Frommlet,
- Daniel Segelcke,
- Esther M. Pogatzki-Zahn,
- Bernhard Voelkl,
- Tim Friede,
- Edgar Brunner,
- Astrid Dempfle,
- Bernhard Haller,
- Marie Juliane Jung,
- Lars Björn Riecken,
- Hans-Georg Kuhn,
- Matthias Tenbusch,
- Lina Maria Serna Higuita,
- Edmond J. Remarque,
- Servan Luciano Grüninger-Egli,
- Katrin Manske,
- Sebastian Kobold,
- Marion Rivalan,
- Lisa Wedekind,
- Juliane C. Wilcke,
- Anne-Laure Boulesteix,
- Marcus W. Meinhardt,
- Rainer Spanagel,
- Simone Hettmer,
- Irene von Lüttichau,
- Carla Regina,
- Ulrich Dirnagl,
- Ulf Toelch
Affiliations
- Natascha Ingrid Drude
- Berlin Institute of Health (BIH) at Charité, BIH QUEST Center for Responsible Research
- Lorena Martinez-Gamboa
- Berlin Institute of Health (BIH) at Charité, BIH QUEST Center for Responsible Research
- Meggie Danziger
- Berlin Institute of Health (BIH) at Charité, BIH QUEST Center for Responsible Research
- Anja Collazo
- Berlin Institute of Health (BIH) at Charité, BIH QUEST Center for Responsible Research
- Silke Kniffert
- Berlin Institute of Health (BIH) at Charité, BIH QUEST Center for Responsible Research
- Janine Wiebach
- Berlin Institute of Health (BIH) at Charité, BIH QUEST Center for Responsible Research
- Gustav Nilsonne
- Berlin Institute of Health (BIH) at Charité, BIH QUEST Center for Responsible Research
- Frank Konietschke
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Institute of Biometry and Clinical Epidemiology
- Sophie K. Piper
- Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Institute of Biometry and Clinical Epidemiology
- Samuel Pawel
- Department of Biostatistics at the Epidemiology, Biostatistics and Prevention Institute, University of Zurich
- Charlotte Micheloud
- Department of Biostatistics at the Epidemiology, Biostatistics and Prevention Institute, University of Zurich
- Leonhard Held
- Department of Biostatistics at the Epidemiology, Biostatistics and Prevention Institute, University of Zurich
- Florian Frommlet
- Medical University of Vienna, CEMSIIS, Section for Medical Statistics
- Daniel Segelcke
- Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Muenster
- Esther M. Pogatzki-Zahn
- Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Muenster
- Bernhard Voelkl
- Animal Welfare Division, University of Bern
- Tim Friede
- Department of Medical Statistics, University Medical Center
- Edgar Brunner
- Department of Medical Statistics, University Medical Center
- Astrid Dempfle
- Institute of Medical Informatics and Statistics, Kiel University and University Hospital Schleswig-Holstein
- Bernhard Haller
- Institute of AI and Informatics in Medicine, Technical University of Munich, TUM School of Medicine
- Marie Juliane Jung
- Leibniz Institute on Aging – Fritz-Lipmann Institute
- Lars Björn Riecken
- Leibniz Institute on Aging – Fritz-Lipmann Institute
- Hans-Georg Kuhn
- Department of Neuroscience and Physiology, Section for Clinical Neuroscience, University of Gothenburg
- Matthias Tenbusch
- Institute of Clinical and Molecular Virology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg
- Lina Maria Serna Higuita
- Institut Für Klinische Epidemiologie Und Angewandte Biometrie (IKEaB) Tübingen Universität
- Edmond J. Remarque
- Biomedical Primate Research Centre (BPRC), Department of Virology
- Servan Luciano Grüninger-Egli
- Applied Statistics Group, Department of Mathematics, University of Zurich
- Katrin Manske
- Division of Clinical Pharmacology, Department of Medicine IV, Klinikum Der Universität München
- Sebastian Kobold
- Division of Clinical Pharmacology, Department of Medicine IV, Klinikum Der Universität München
- Marion Rivalan
- Charité -Universitätsmedizin Berlin, FEM & Exzellenzcluster NeuroCure, Animal Behavior Phenotyping Facility
- Lisa Wedekind
- Institute of Medical Statistics, Computer and Data Sciences, Jena University Hospital
- Juliane C. Wilcke
- Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig Maximilian University of Munich
- Anne-Laure Boulesteix
- Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig Maximilian University of Munich
- Marcus W. Meinhardt
- Institute for Psychopharmacology, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg
- Rainer Spanagel
- Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg
- Simone Hettmer
- Division of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, University Medical Center Freiburg, University of Freiburg
- Irene von Lüttichau
- Department of Pediatrics and Children’s Cancer Research Center, TUM School of Medicine, Technical University of Munich
- Carla Regina
- Kinderklinik München Schwabing- Klinik Und Poliklinik Für Kinder- Und Jugendmedizin, Klinikum Schwabing, München Klinik GmbH und Klinikum Rechts Der Isar (AöR) der Technischen Universität München
- Ulrich Dirnagl
- Berlin Institute of Health (BIH) at Charité, BIH QUEST Center for Responsible Research
- Ulf Toelch
- Berlin Institute of Health (BIH) at Charité, BIH QUEST Center for Responsible Research
- DOI
- https://doi.org/10.1186/s41231-022-00130-8
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 13
Abstract
Abstract Clinical translation from bench to bedside often remains challenging even despite promising preclinical evidence. Among many drivers like biological complexity or poorly understood disease pathology, preclinical evidence often lacks desired robustness. Reasons include low sample sizes, selective reporting, publication bias, and consequently inflated effect sizes. In this context, there is growing consensus that confirmatory multicenter studies -by weeding out false positives- represent an important step in strengthening and generating preclinical evidence before moving on to clinical research. However, there is little guidance on what such a preclinical confirmatory study entails and when it should be conducted in the research trajectory. To close this gap, we organized a workshop to bring together statisticians, clinicians, preclinical scientists, and meta-researcher to discuss and develop recommendations that are solution-oriented and feasible for practitioners. Herein, we summarize and review current approaches and outline strategies that provide decision-critical guidance on when to start and subsequently how to plan a confirmatory study. We define a set of minimum criteria and strategies to strengthen validity before engaging in a confirmatory preclinical trial, including sample size considerations that take the inherent uncertainty of initial (exploratory) studies into account. Beyond this specific guidance, we highlight knowledge gaps that require further research and discuss the role of confirmatory studies in translational biomedical research. In conclusion, this workshop report highlights the need for close interaction and open and honest debate between statisticians, preclinical scientists, meta-researchers (that conduct research on research), and clinicians already at an early stage of a given preclinical research trajectory.
Keywords
- Confirmatory preclinical studies
- Confirmatory preclinical multicenter studies
- Preclinical multicenter studies
- Robust evidence
- Reproducibility
- Clinical translation